The Comparative Medicine and Bioimage Centre of Catalonia celebrates its fifth anniversary
CMCiB celebrated its first five years of activity with a symposium dedicated to pioneering biomedical research at CosmoCaixa.
At the IGTP TODAY
News
Progress in developing specific immunotherapies for type 1 diabetes
Researchers from IGTP and Ahead Therapeutics have been exploring a treatment based on liposome-type nanoparticles to address the autoimmunity of type 1 diabetes for years. A study recently published in the Journal of Autoimmunity examines the response of macrophages to this immunotherapy, serving as a preliminary step before clinical trials.
Can Ruti celebrates a Rare Disease Day symposium highlighting the importance of research to help patients
On Thursday 29 February, the Germans Trias Hospital hosted the 'International Rare Disease Day Symposium'. Health professionals and researchers from the Hospital and IGTP discussed their work in advancing the field of rare diseases. Representatives from patient associations of these diseases also participated.
A year in review: 2023 highlights at IGTP
In 2023, the IGTP has continued to make significant strides in its mission. Here, we review the year's top news stories, reflecting the persistent drive and collaborative spirit that underpin this institution.
- Research
Type 1 diabetes research sheds light on biomarkers in partial remission phase
Researchers from the IGTP have led a comprehensive review study on biomarkers for the often-overlooked partial remission phase of type 1 diabetes, in collaboration with experts in β-cell biology and regeneration from the Diabetes Research Institute in Miami. The study has been published in the journal Trends in Endocrinology and Metabolism.
The podcast 'Un bri de ciència' explores type 1 diabetes in its second episode
The new episode of the podcast 'Un bri de ciència' is presented under the title "La diabetis tipus 1: quan la defensa t'ataca" (Type 1 diabetes: when your defences attack you). Researcher Marta Vives Pi explains the problems of autoimmune diseases, with an emphasis on type 1 diabetes.
- Research
Studying partial remission of type 1 diabetes in children: New biomarkers and the immunoregulatory role of microRNA
A study led by researchers from IGTP's Immunology of Diabetes group has identified new microRNA as biomarkers for the partial remission phase, also known as "honeymoon phase", of type 1 diabetes, and has linked the miR-30d-5p microRNA to immunoregulatory processes that may take place during this phase.
- Research
Two studies from the Immunology group on autoimmunity and hematopoietic stem cells show promising therapeutic potential
The first study, published in Nanomedicine: Nanotechnology, Biology and Medicine, seeks a strategy to safely and definitevely restore self-tolerance in autoimmune diseases; the second, in Archivum Immunologiae et Therapiae Experimentalis, bets on making the most of umbilical cord blood cells, key against hematological diseases
- Research
No increased risk of diabetes type 1 for children of women treated with betamethasone during pregnancy
The Immunology of Diabetes group have published a study evaluating the effect of prenatal exposure to betamethasone on the risk of developing diabetes type 1 in the Journal of Diabetes Research.
- Research
New biomarkers to monitor and predict the remission phase (honeymoon) in children with type 1 diabetes
A study led by researchers from the Germans Trias i Pujol Research Institute (IGTP) and the Parc Tauli Hospital published in Frontiers in Immunology shows that a sample of peripheral blood can be used to identify levels of cells and molecules of the immune system that are specifically altered during the remission phase in paediatric type 1 diabetes (T1D). These can be used to monitor this phase and predict the progress of the disease.
